Astellas to terminate development of anti-human antibody for RA

26 Oct 2009

1

Tokyo-headquartered Astellas Pharma today announced that it has decided to terminate the development of its anti-human osteopontin antibody for rheumatoid arthritis, which it was co developing under the development code ASK8007, with Japanese drug developer Chemo-Sero-Therapeutic Research Institute (Kaketsuken)

Astellas said that along with Immuno-Biological Laboratories Co., Ltdit had oncluded a worldwide licensing agreement, which granted Astellas the exclusive rights to develop, manufacture, and market anti-human osteopontin antibodies, for therapeutic use in March 2006.

It further said "Astellas and Kaketsuken carried out Phase I for ASK8007 for RA; however, have concluded terminating the development for the field of RA by evaluating the result of the study comprehensively."

Astellas is now considering a possible application of it to other indications than RA.

Business History Videos

History of hovercraft Part 3...

Today I shall talk a bit more about the military plans for ...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of hovercraft Part 2...

In this episode of our history of hovercraft, we shall exam...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Hovercraft Part 1...

If you’ve been a James Bond movie fan, you may recall seein...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Trams in India | ...

The video I am presenting to you is based on a script writt...

By Aniket Gupta | Presenter: Sheetal Gaikwad

view more